covid image

Update on our COVID-19 Vaccine Candidate

Vaccines remain one of the most effective ways to prevent COVID-19 infections and serious disease. With vaccination rates around the globe still increasing, recent estimates suggest that the majority of adults could be vaccinated against COVID-19 by mid-2022.1 However, current vaccines may not optimally protect against new variants and protection from both natural and vaccine immunity may diminish over time.2

In the rapidly evolving landscape of the pandemic, we have taken a forward-looking approach to our vaccine development. On December 15th, Sanofi and GSK announced positive preliminary results of a study investigating the safety and immune response with their vaccine candidate as a booster regardless of primary vaccine received (mRNA or adenovirus vector-based vaccines). Sanofi continues its ongoing phase 3 trial of the vaccine following a recommendation from the Data Safety and Monitoring Board (DSMB), an independent data oversight body. The DSMB identified no safety concerns and recommended the trial continue into early 2022 to collect and provide the data necessary for regulatory submissions.

Our Adjuvanted Recombinant Protein-based Vaccine Candidate

The vaccine antigen is the spike protein that will stimulate the immune system to produce antibodies against the virus

Our contribution to the global supply

Covid-19

Our Commitment to Fighting COVID-19

Throughout the ongoing pandemic, we have joined forces to fight COVID-19

Frequently Asked Questions (FAQ)

COVID-19 Press Releases

[Pagination JS]

The Impact of COVID-19 on the Prevention and Diagnosis of other Diseases

molecule

Vaccines: our best line of defense against infectious diseases like COVID-19

Upshot Serie Article 2

Critical Routine Vaccinations: Getting Back on Track

Preventing the Preventable: Influenza Vaccination in the Time of COVID-19

World Polio Day: Driving Polio Out of Sight, Never Out of Mind

Covid picture

Developing COVID-19 Vaccines: Behind the Scenes 

People with Cancer during COVID-19

Supporting People with Cancer during COVID-19

COVID-19 Highlights Value of Self-Care as First Line of Defense

References

  1. GAVI. Covax Global Supply Forecast. Available at: https://www.gavi.org/sites/default/files/covid/covax/COVAX%20Supply%20Forecast.pdf. Last accessed October 2021.
  2. Nature. COVID vaccines protect against Delta, but their effectiveness wanes. 19 August 2021. Available at: https://www.nature.com/articles/d41586-021-02261-8. Last accessed October 2021